• Gwilym Attwell, principal, Fish & Richardson P.C.
• Stephanie Baldwin, senior manager of investor relations and corporate communications, Antares Pharma Inc.
• Keith Brownlie, partner, Ernst & Young
• Geert Cauwenbergh, Ph.D., managing director, Phases123 LLC and chairman & CEO, RHEI Pharmaceuticals
• Peter DeComo, CEO, Renal Solutions, Inc.
• Michael Dowzicky, M.S., MT ASCP, senior director, global medical affairs; infectious disease and transplantation group, Wyeth Pharmaceuticals
• Steve Elek, III, partner, transaction services, PricewaterhouseCoopers, LLP
• Robert Esposito, national lead partner, transaction services, KPMG LLP
• Ulrich Grau, Ph.D., president & CEO, Lux Biosciences, Inc.
• Walter Greenblatt, managing director, Walter Greenblatt & Associates
• Anand Gumaste, president & CEO, MicroDose Technologies, Inc.
• Thomas Hess, CPA, senior vice president of finance and CFO, Yaupon Therapeutics, Inc.
• Jane Hollingsworth, CEO, NuPathe Inc.
• Russel Kaufman, M.D., president & CEO, The Wistar Institute
• Gerard Norton, Ph.D., partner, Fox Rothschild LLP
• Robert Pietrusko, Pharm.D., vice president, global regulatory affairs and quality, ViroPharma Incorporated
• Jason Rubin, president and founder, The Redstone Group, LLC
• Randall Sunberg, partner, Morgan, Lewis & Bockius, LLP
• Bob Ward, vice president, alliance management and business development, NPS Pharmaceuticals Inc.
• Sheryl Williams, vice president, public affairs, Cephalon, Inc.
• Dennis Willson, president & CEO, Cytokine PharmaSciences
• Paul Woitach, president & CEO, Pharmaceutical Advisors LLC

Gwilym Attwell, principal, Fish & Richardson P.C.

Gwilym Attwell is a principal in Fish & Richardson's Delaware office, managing the local presence of Fish's highly regarded patent prosecution and counseling practice. Mr. Attwell's practice emphasizes patent prosecution, opinions, due diligence studies, and client counseling in biotechnology, pharmaceuticals, and medical sciences. Mr. Attwell's projects have involved novel genes, receptors, antibodies, vaccines, diagnostics, formulations and therapeutics.

Mr. Attwell has participated as a speaker at BIO-Europe (2007); Biotech PA NJ DE (2006, 2007); Temple University School of Law (2008); and the University of Pennsylvania (2006, 2007).  Mr. Attwell is on the programming committees for BIO 2009, Pennsylvania Bio, and Delaware BIO.

Stephanie Baldwin, senior manager of investor relations and corporate communications, Antares Pharma Inc.

Ms. Baldwin is senior manager of investor relations and corporate communications for Antares Pharma, Inc., where she created and implemented the formal strategic investor relations program resulting in new sell-side analyst coverage (four) and new institutional investors ($50M+). Previously, she managed the communications programs for private companies as well as governmental body (judicial). Ms. Baldwin serves as vice president on the Board of the National Investor Relations Institute (NIRI), Philadelphia Chapter and is a Charter Member of the NIRI BioPharma Roundtable. She currently serves as a Biotech 2008 communications committee co-chair for BioNJ.

Keith Brownlie, partner, Ernst & Young

Mr. Brownlie is the metro New York area life science industry leader.  He has been with Ernst & Young for more than 34 years.  He has extensive experience with SEC registration statements including IPOs and recurring reporting.  His industry and professional qualifications include extensive experience auditing and facilitating the public offerings of entrepreneurial companies, mergers and acquisitions, financing alternatives and other entrepreneurial business issues.  Mr. Brownlie is a member of Ernst & Young's National Life Sciences Committee, the New Jersey, New York and Connecticut Society of CPAs, and the American Institute of CPAs. He is also a former vice president and trustee of the New Jersey Society of CPAs and a co-chair of the Annual Joint Symposium held by BioNJ and PA Bio.  He is a frequent speaker on the Life Science industry and has written numerous articles on trends in the industry.  Mr. Brownlie is a graduate of Lehigh University with a BS in Accounting. 

Geert Cauwenbergh, Ph.D., managing director, Phases123 LLC and chairman & CEO, RHEI Pharmaceuticals

In February 2008, Dr. Geert Cauwenbergh founded Phases123 LLC, a company focused on identifying high potential health care technology platforms and companies. Phases123 enables accelerated growth by building management teams, facilitating product and business development and providing access to capital and geographical expansion.  Before Phases123, he founded Barrier Therapeutics Inc. in 2001 as a biopharmaceutical company with emphasis on the R&D of novel agents for skin diseases.

During his career, he has held senior positions at Johnson and Johnson and Janssen Pharmaceutica.  He received his Ph.D. in Medical Sciences from the Catholic University of Leuven, Faculty of Medicine, where he also completed his Masters and undergraduate work.

Peter DeComo, CEO, Renal Solutions, Inc.

Pete DeComo became the CEO of Renal Solutions, Inc. (RSI), a wholly-owned subsidiary of Fresenius Medical Care Holdings (FMCHI) subsequent to a merger on November 26, 2007.  Prior to this he was the chairman, CEO and co-founder of RSI, which was developing a revolutionary dialysis technology for patients with kidney failure.  Total consideration paid by FMCHI was $200 MM at a pre-revenue stage.  Mr. DeComo is a director on the boards of the Pittsburgh Life Sciences Greenhouse and the Pittsburgh Technology Council in addition to being a director with three early-stage companies.  Mr. DeComo is the recipient Ernst & Young "Entrepreneur of the Year Award" in Healthcare for 2008 and the Pittsburgh Venture Capital Association "Entrepreneur of the Year" for 2008.

Michael Dowzicky, M.S., MT ASCP, senior director, global medical affairs; infectious disease and transplantation group, Wyeth Pharmaceuticals

Michael Dowzicky, M.S., MT ASCP graduated from Thomas Jefferson University with a Master of Science degree in Clinical Microbiology in 1989.  At Wyeth, he is responsible for the day-to-day implementation and management of the Global Phase IV program within infectious disease including Clinical Trials.  Mr. Dowzicky has direct contact with Wyeth country affiliates globally to guide programs to each of their respective market needs.  Prior to joining Wyeth Pharmaceuticals in 2000, he worked for Rhone Poulenc Rorer (RPR) as part of a large team responsible for the microbiological development work on Synercid and ultimately its NDA filing.  Prior to joining RPR in 1995 he worked for Zeneca Pharmaceuticals and was a member of the microbiology team responsible for the development of the microbiological profile of Meropenem. 

Steve Elek, III, partner, transaction services, PricewaterhouseCoopers, LLP

Mr. Elek leads the Healthcare Practice in PwC's Transaction Services Group.  He has more than twenty-five years of experience in various healthcare industry sectors, delivering a wide range of merger, acquisition, divestiture, joint venture and corporate finance related services.  His sector experience includes pharmaceutical and life science, medical device, health insurance/managed care, hospital, long-term care, rehabilitation centers, home care and laboratories.  Mr. Elek, a CPA and attorney, is a frequent speaker and author.  He had also served as president of the Association for Corporate Growth's Philadelphia Chapter and chairman of its Board of Directors.

Robert Esposito, national lead partner, transaction services, KPMG LLP

Robert Espositio's career with KPMG has spanned over the past 32 years.  He has been a partner in transaction services and the national sector leader for pharmaceuticals, biotechnology, medical devices, and pharmaceutical services since 1995.  From 1990 to 2000, he was the national sector leader in biotechnology and life sciences.  He also spent two years in KPMG's Executive Office Department of Professional Practice. Mr. Espositio was elected to KPMG"s partnership in 1987.  Mr. Espositio provides financial advisory, strategic planning and transaction-related professional services such as business assessment, transaction strategy, project management, due diligence (financial, commercial, business), IPO-readiness services, carve-out & divestiture services, transaction integration, and transaction structuring and accounting advisory services.  He graduated Summa Cum Laude from Rider University.

Ulrich Grau, Ph.D., president & CEO, Lux Biosciences, Inc.

With an accomplished career in the biotechnology and pharmaceutical industries, Ulrich Grau, Ph.D., is co-founder, president and CEO of Lux Biosciences Inc., a clinical-stage biotechnology company specializing in ophthalmic diseases.

Dr. Grau was Enzon's CSO from 2002 to January 2005, upgrading Enzon's R&D capabilities based on partnering and the company's proprietary macromolecular engineering technologies. Prior, he served as president of R&D and member of the Executive Board at BASF Pharma/ Knoll with, among others, Humira® in its pipeline.  Dr. Grau also had the role of senior vice president and R&D integration officer at Aventis Pharma, and of senior vice president of global product realization at Hoechst Marion Roussel. Lantus® is based on his discoveries during his early years in the industry. 

Walter Greenblatt, managing director, Walter Greenblatt & Associates

Walter Greenblatt, a veteran life science-focused investment banker, raises seed capital and early institutional funding for fast-growing life science startups including WuXi Pharmatech, MedAvante, Advanced BioHealing and many others in various therapeutic areas.  In addition to raising early-stage capital, he closes M&A and business development transactions for clients developing therapeutics, medical devices and pharmaceutical services.

He is an experienced entrepreneur and "hands-on" operating executive himself, having founded, grown and sold a profitable business.  Before that, he was with Bain & Company.  Mr. Greenblatt received his MBA from Harvard Business School after graduating from Yale and receiving a Masters in Economics from Oxford.

Anand Gumaste, president & CEO, MicroDose Technologies, Inc.

Anand Gumaste co-founded MicroDose Technologies, Inc. in 1998 and has served as a member and chairman of the Board of Directors since MicroDose's inception.  Dr. Gumaste is a principal inventor of a majority of MicroDose's core technologies.  Prior to MicroDose, Dr. Gumaste co-founded Strategic Consulting Group, of Trenton, NJ, which focused on developing effective managed healthcare market strategies for medical device manufacturers.  Before this, Dr. Gumaste was the director of electronics at PA Consulting Group, Princeton, NJ, spending 11 years there, with responsibilities including developing products and technology management strategies for major corporations.  Dr. Gumaste also sits on the Boards of QDose and MicroDose Defense Products.

Thomas Hess, CPA, senior vice president of finance and CFO, Yaupon Therapeutics, Inc.

Thomas Hess, CPA, senior vice president of finance and CFO of Yaupon Therapeutics, Inc., is a financial executive with 20 years of domestic and international experience. Prior to joining Yaupon Therapeutics, Mr. Hess was the vice president, finance and CFO of Adolor Corporation from 2005 to 2008. From 2003 until joining Adolor Corporation, Mr. Hess was corporate controller of Vicuron Pharmaceuticals, Inc, a biopharmaceutical company that was acquired by Pfizer Inc. in 2005 for $1.9 billion. Mr. Hess was also with KPMG LLP for ten years as a senior manager. Mr. Hess has a BS in accounting from Pennsylvania State University and a MBA in Finance from the University of Pittsburgh. 

Jane Hollingsworth, CEO, NuPathe Inc.

Ms. Hollingsworth is co-founder and CEO of NuPathe Inc., a specialty pharmaceutical company focusing on neurology and psychiatry. NuPathe is developing the first-ever migraine patch and a long-acting treatment for Parkinson's disease.  Prior to NuPathe, Ms. Hollingsworth was co-founder and executive vice president of Auxilium Pharmaceuticals, a specialty pharmaceutical company with a focus on urology. Earlier in her career she served as vice president, secretary and general counsel of IBAH, Inc., a publicly-traded, multi-national CRO.  Prior to IBAH, she was a commercial litigator at Montgomery, McCracken, Walker & Rhoads and law clerk to Federal Judge Jane R. Roth. 

Russel Kaufman, M.D., president & CEO, The Wistar Institute

Russel Kaufman, M.D. is president and CEO of The Wistar Institute and director of The Wistar Cancer Center. Previously he was vice dean and associate vice chancellor at the Duke University School of Medicine. He has held leadership positions in academic organizations and on committees within the NIH, the National Academy of Sciences and the American Cancer Society. His research focuses on genetics, cancer, and blood diseases. He serves on many boards including the Science Center, BioAdvance, The University of the Arts, Neuland Laboratories and the Chamber of Commerce. He is member of WHYY's Health and Science Desk Advisory Committee.

Gerard Norton, Ph.D., partner, Fox Rothschild LLP

Gerard Norton, Ph.D., Esq., is chair of Fox Rothschild's Intellectual Property Department, and co-chair of the Biotech Pharma Practice Group. His practice focuses on both litigation of intellectual property rights and prosecution of patents, trademarks and copyrights in the US and abroad.  He has successfully litigated complex matters pertaining to patent, trademark, copyright, trade secret, and breach of contract disputes.  Dr. Norton also counsels clients regarding the validity and scope of intellectual property rights, the evaluation and development of intellectual property portfolios, and the review of intellectual property matters relevant to acquisitions and divestitures.  Clients include pharmaceutical, biotechnology, chemical, and medical device companies, universities and non-profit organizations.

Robert Pietrusko, Pharm.D., vice president, global regulatory affairs and quality, ViroPharma Incorporated

Jason Rubin, president and founder, The Redstone Group, LLC

Jason Rubin is president and founder of The Redstone Group, LLC, a healthcare communications consulting firm.  He has more than twenty years of communications and management consulting experience advising biotechnology, pharmaceutical, and technology companies on a wide range of public- and investor-relations issues. 

Previously, he was a director of the biotechnology group at Hill and Knowlton Public Affairs in Washington, D.C., vice president and senior communications officer at Immunex, Cephalon, Centocor, and Incyte, and a board member of the Pennsylvania Biotechnology Association. 

He received a bachelor of arts degree in geology from Middlebury College and a master of science degree in management from the Sloan School of Management at MIT.

Randall Sunberg, partner, Morgan, Lewis & Bockius, LLP

Randall Sunberg is a partner in Morgan Lewis' Business and Finance Practice, vice chair of the firm's Life Sciences Interdisciplinary Group, and co-chair of the firm's Life Sciences Transactions Practice.  Mr. Sunberg's clients range from early-stage biotechnology start-ups to global pharmaceutical companies, as well as specialty pharma, medical device, and other technology companies. His clients also include private equity, venture capital, and investment banking firms focused on the life sciences industry. Mr. Sunberg is admitted to practice in New Jersey, Pennsylvania, New York, and Missouri.

Bob Ward, vice president, alliance management and business development, NPS Pharmaceuticals Inc.

Mr. Ward, vice president, for alliance management and business development at NPS Pharmaceuticals of Bedminster, is responsible for global/regional partnerships. Two decades of biopharmaceutical experience range from discovery research at Genentech to business development and brand marketing with Bristol-Myers Squibb. He received a B.S. in Biological Sciences and a B.A. in Physiological Psychology from the University of California, Santa Barbara; an M.A. in Immunology from the Johns Hopkins University School of Medicine; and an M.S. in Management of Technology from NJIT.

Sheryl Williams, vice president, public affairs, Cephalon, Inc.

Sheryl Williams is currently vice president, public affairs at Cephalon, Inc. and responsible for the company's global communications function.  Ms. Williams joined Cephalon in 1999 to develop their product public relations function.   Prior to joining Cephalon, she managed CNS and oncology brands globally for the former Rhone-Poulenc Rorer. 

Ms. Williams' background includes more than 25 years of experience in corporate and not-for-profit healthcare and healthcare-related organizations.  During her career, she has worked for a diverse group of companies and won several awards for outstanding communications programs.  Her career path includes stints with Baxter Healthcare, Encyclopaedia Britannica, the Alzheimer's Association and the former Rhone-Poulenc Rorer.  Ms. Williams is an alumna of Creighton University in Omaha, NE.

Dennis Willson, president & CEO, Cytokine PharmaSciences

Mr. Willson began his career in the pharmaceutical industry as an attorney with Abbott Laboratories, later training in various marketing and financial positions at Abbott's Argentine subsidiary. He moved to Rorer International in 1985, where ultimately he held the position of managing director of Rorer Spain. Following the merger with Rhone Poulenc, Mr. Willson left Rorer to join Carrington Laboratories in Dallas, where he served as executive vice president before coming to Cytokine PharmaSciences (CPSI). He served as vice president of business development for CPSI until June 2002, at which time he was appointed to his current role as president and CEO.

Paul Woitach, president & CEO, Pharmaceutical Advisors LLC

Paul Woitach is managing partner of Pharmaceutical Advisors LLC, providing life sciences R&D support and technical diligence.  They accelerate progress and manage risk through an integrated expert approach.  Previously, he led a turnaround as CEO of IGI, was general manager of Mettler Toledo's lab instrument business and vice president and executive director with Kodak's Medical Division.  He has served on the Boards of public companies and of business incubators.  He holds an M.B.A. from the Simon School of Business.